Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial

20260 citationsJournal Articlehybrid Open Access

Authors

Agnès Linglart · Inserm

Volker Böttcher · Endokrinologikum

Michael Højby · Novo Nordisk (Denmark)

Kamil Soltysik · Novo Nordisk (Denmark)

C. Longui · Irmandade da Santa Casa de Misericórdia de São Paulo

Lawrence Silverman · Goryeb Children's Hospital

Kenichi Kashimada ·

Abstract

Somapacitan provides similar efficacy, safety, and tolerability as daily GH in short children born SGA after 52 weeks of treatment. Somapacitan may be an attractive alternative to daily GH in this population, reducing treatment burden to improve adherence and treatment outcomes.

Topics & Keywords

Birth, Development, and Health Pregnancy and preeclampsia studies Neonatal Respiratory Health Research

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: European Journal of Endocrinology

Volume 194, Issue 3, pp. 311-325

DOI: 10.1093/ejendo/lvag021

Field-Weighted Citation Impact: 0.00